12.03.2014 • NewsBayerDede Willamshealthcare

Bayer to Invest More Than €500 Million in Haemophilia Pipeline

BayerHealthcare plans to invest more than €500 million at its sites in Wuppertal and Leverkusen, Germany, to expand capacity for production of its recombinant factor VIII haemophilia drug.

Investigational therapy options for haemophilia, including a plama protein-free upgrade of the Factor VIII drug Kogenate and a long-acting recombinant FVIII are currently in Phase III chemical trials. In February, Bayer announced positive results from the PROTECT VIII trials evaluating its site-specific PEGylated recombinant FVIII drug.

The investment is one of the largest in the history of Bayer HealthCare said the sub-group's CEO Oliver Brandicourt. It will create around 500 new jobs at the two sites up to 2020.

Establishing a base in Germany for Kogenate, currently manufactured exclusively in Berkeley, California, in the U.S., will help the company prepare for production of the expected new therapy options and address the growing demand in this therapeutic area, Brandicourt said.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.